Oslo University Hospital Rikshospitalet was the site of an experimental autologous dendritic cell (DC) vaccine that was tested in an open-label, Phase I/II clinical trial in Acute Myeloid Leukemia (AML) patients. With the primary outcomes announced by Munich-based...
AML
Category
FDA Clears Mustang Bio’s IND for MB-102 (CD123-CAR T)
Mustang Bio, Inc (MBIO) reports that the U.S. Food and Drug Administration (FDA) has approved the Company’s investigational new dug application (IND) in acute myeloid leukemia (AML) blastic plasmacytoid dendritic cell neoplasm (BPDCN) and high-risk myelodysplastic...
Mustang Bio’s MB-102 Granted Orphan Drug Designation for AML
MB-102, a CAR T-cell therapy under development by Mustang Bio, Inc. has received orphan drug designation for Acute Myeloid Leukemia (AML). What is MB-102? CD123 is over expressed in 75-89% of AML patients and over 90% in Blastic plasmacytoid dendritic cell neoplasm...
VCU Massey Cancer Center Identifies Novel Combo Drug Effective Against AML During Preclinicals
Scientists at VCU Massey Cancer Center found that a novel combination of drugs is effective against acute myeloid leukemia (AML) in preclinical models. The findings, recently published in the Journal of Cancer Research, could lead to new and improved treatments for...
(HM)-SCREEN-Japan 01 Program Bringing Precision Medicine Research to AML Patients in Japan
Iqra Farooq with AML Global Portal writes the prognosis of younger patients with acute myeloid leukemia (AML) has improved with the development of allogeneic hematopoietic stem cell transplantation (allo-HSCT) and advanced supportive care. But, in most elderly...
Nanfang Hospital Southern Medical Univ. Study Shows Sorafenib Associated Helps Patients with FLT3-ITD AML
Iqra Farooq of AML Global reports approximately 25% of patients with acute myeloid leukemia (AML) have internal tandem duplication of FMS-like tyrosine kinase 3 (FLT3-ITD) mutations and survival is often inferior due to high relapse rates and short remission periods....
Columbia Investigator Discusses Targeted Alpha-particle Therapy for Hematologic Malignancies
Uro Today reports well known physician Dr. Joseph G. Jurcic, after reviewing the early treatment of acute myelogenous leukemia (AML) with Bi213-Lintuzumab when contrasted with beta-emitters I132 and Y90, found the alpha therapy was far superior in absorbed dose to the...
Innovative Clinical Trial Taking on Acute Myeloid Leukemia
Launched in 2016 by The Leukemia & Lymphoma Society (LLS), the Beat AML Master Clinical Trial represents a groundbreaking collaborative trial targeting acute myeloid leukemia (AML). From humble beginnings in the 1940s New York to present day, the Leukemia &...
VOR Biopharma Raises $42 Million to to Fight Hematological Malignancies such as Leukemia
Led by an elite group of investors including Johnson & Johnson Innovation and Novartis Institute for BioMedical Research, Vor Biopharma, an immuno-oncology company pioneering engineered hematopoietic stem cell (HSC) therapies for the treatment of hematological...
Genetic Screening Rapidly Links Elderly AML Patients to Targeted Therapy
Early results from the BEAT AML trial are promising. Brittany K. Rangon, MD was interviewed by Healio. She is a leading leukemia transplant specialist in the department of hematologic oncology and blood disorders at the Levine Cancer Institute, Carolinas Healthcare...
Pfizer Study Evaluates Addition of Glasdegib in AML & High-Risk MDS Patients
A Pfizer-sponsored study recently generated clinical results. This was a study to evaluate PF-04449913 (an inhibitor of the Hedgehog pathway) in Acute Myeloid Leukemia and high-risk Myelodysplastic Syndrome in combination with standard agents used to treat these...